Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens
Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-l...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infectious Diseases 2024-06, Vol.11 (6), p.ofae296 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | ofae296 |
| container_title | Open Forum Infectious Diseases |
| container_volume | 11 |
| creator | Lodise, Thomas P Kaye, Keith S Santerre Henriksen, Anne Kahlmeter, Gunnar |
| description | Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for
to mecillinam-including resistant phenotypes such as extended-spectrum β-lactamase-producing
-exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including
spp.,
spp., and
spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI. |
| doi_str_mv | 10.1093/ofid/ofae296 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11167674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A804159849</galeid><sourcerecordid>A804159849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-79dcecb9477b59c998b1d5bb15e4e43fea84440df739dd83c55b355fb461d3cd3</originalsourceid><addsrcrecordid>eNpVkl1vFCEUhidGY5vaO68Nl164FQaYAW_MZmO1SRtN03pLGDjMYhhYB3ZN_40_VTa7bWpI-Drv-3DIOU3zluALgiX9mJy3ddLQyu5Fc9rSViyE5P3LZ_uT5jznXxhjQjDHvXzdnFAhOkGxOG3-3sLOwx-UHCprQFcR_fRlTujGmzkNPoU0eqMDWprid7487IU3YHwIPuoJLUftYy5olaYpRXQ_p40u6zRCzMjXczRp2oRKKGBrtHrmB3Q3a1PqUw4qNMVP6DKZbUbVfwvZ56JjQT8eMW-aV06HDOfH9ay5v_xyt_q2uP7-9Wq1vF4YSmVZ9NIaMINkfT9waaQUA7F8GAgHBow60IIxhq3rqbRWUMP5QDl3A-uIpcbSs-bzgbvZDhNUWCyzDmoz-6nmrJL26v9I9Gs1pp0ihHR917NKeH8kzOn3FnJRk88GQtAR0jYrirtekrZrZZVeHKSjDqB8dKkiTR0WJm9SBOfr_VJgRrgUbG_4cDDUquQ8g3tKjGC17wS17wR17IQqf_f8M0_ix7rTf5mAtTQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067912629</pqid></control><display><type>article</type><title>Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Lodise, Thomas P ; Kaye, Keith S ; Santerre Henriksen, Anne ; Kahlmeter, Gunnar</creator><creatorcontrib>Lodise, Thomas P ; Kaye, Keith S ; Santerre Henriksen, Anne ; Kahlmeter, Gunnar</creatorcontrib><description>Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for
to mecillinam-including resistant phenotypes such as extended-spectrum β-lactamase-producing
-exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including
spp.,
spp., and
spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofae296</identifier><identifier>PMID: 38868308</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Beta lactamases ; Care and treatment ; Drug resistance in microorganisms ; Editor's Choice ; Health aspects ; Microbiology ; Pivmecillinam ; Review ; Urinary tract infections</subject><ispartof>Open Forum Infectious Diseases, 2024-06, Vol.11 (6), p.ofae296</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</rights><rights>COPYRIGHT 2024 Oxford University Press</rights><rights>The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c339t-79dcecb9477b59c998b1d5bb15e4e43fea84440df739dd83c55b355fb461d3cd3</cites><orcidid>0000-0002-4730-0655 ; 0000-0003-2051-1732</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167674/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167674/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38868308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lodise, Thomas P</creatorcontrib><creatorcontrib>Kaye, Keith S</creatorcontrib><creatorcontrib>Santerre Henriksen, Anne</creatorcontrib><creatorcontrib>Kahlmeter, Gunnar</creatorcontrib><title>Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens</title><title>Open Forum Infectious Diseases</title><addtitle>Open Forum Infect Dis</addtitle><description>Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for
to mecillinam-including resistant phenotypes such as extended-spectrum β-lactamase-producing
-exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including
spp.,
spp., and
spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI.</description><subject>Beta lactamases</subject><subject>Care and treatment</subject><subject>Drug resistance in microorganisms</subject><subject>Editor's Choice</subject><subject>Health aspects</subject><subject>Microbiology</subject><subject>Pivmecillinam</subject><subject>Review</subject><subject>Urinary tract infections</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkl1vFCEUhidGY5vaO68Nl164FQaYAW_MZmO1SRtN03pLGDjMYhhYB3ZN_40_VTa7bWpI-Drv-3DIOU3zluALgiX9mJy3ddLQyu5Fc9rSViyE5P3LZ_uT5jznXxhjQjDHvXzdnFAhOkGxOG3-3sLOwx-UHCprQFcR_fRlTujGmzkNPoU0eqMDWprid7487IU3YHwIPuoJLUftYy5olaYpRXQ_p40u6zRCzMjXczRp2oRKKGBrtHrmB3Q3a1PqUw4qNMVP6DKZbUbVfwvZ56JjQT8eMW-aV06HDOfH9ay5v_xyt_q2uP7-9Wq1vF4YSmVZ9NIaMINkfT9waaQUA7F8GAgHBow60IIxhq3rqbRWUMP5QDl3A-uIpcbSs-bzgbvZDhNUWCyzDmoz-6nmrJL26v9I9Gs1pp0ihHR917NKeH8kzOn3FnJRk88GQtAR0jYrirtekrZrZZVeHKSjDqB8dKkiTR0WJm9SBOfr_VJgRrgUbG_4cDDUquQ8g3tKjGC17wS17wR17IQqf_f8M0_ix7rTf5mAtTQ</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Lodise, Thomas P</creator><creator>Kaye, Keith S</creator><creator>Santerre Henriksen, Anne</creator><creator>Kahlmeter, Gunnar</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4730-0655</orcidid><orcidid>https://orcid.org/0000-0003-2051-1732</orcidid></search><sort><creationdate>202406</creationdate><title>Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens</title><author>Lodise, Thomas P ; Kaye, Keith S ; Santerre Henriksen, Anne ; Kahlmeter, Gunnar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-79dcecb9477b59c998b1d5bb15e4e43fea84440df739dd83c55b355fb461d3cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Beta lactamases</topic><topic>Care and treatment</topic><topic>Drug resistance in microorganisms</topic><topic>Editor's Choice</topic><topic>Health aspects</topic><topic>Microbiology</topic><topic>Pivmecillinam</topic><topic>Review</topic><topic>Urinary tract infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lodise, Thomas P</creatorcontrib><creatorcontrib>Kaye, Keith S</creatorcontrib><creatorcontrib>Santerre Henriksen, Anne</creatorcontrib><creatorcontrib>Kahlmeter, Gunnar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open Forum Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lodise, Thomas P</au><au>Kaye, Keith S</au><au>Santerre Henriksen, Anne</au><au>Kahlmeter, Gunnar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens</atitle><jtitle>Open Forum Infectious Diseases</jtitle><addtitle>Open Forum Infect Dis</addtitle><date>2024-06</date><risdate>2024</risdate><volume>11</volume><issue>6</issue><spage>ofae296</spage><pages>ofae296-</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for
to mecillinam-including resistant phenotypes such as extended-spectrum β-lactamase-producing
-exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including
spp.,
spp., and
spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>38868308</pmid><doi>10.1093/ofid/ofae296</doi><orcidid>https://orcid.org/0000-0002-4730-0655</orcidid><orcidid>https://orcid.org/0000-0003-2051-1732</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2328-8957 |
| ispartof | Open Forum Infectious Diseases, 2024-06, Vol.11 (6), p.ofae296 |
| issn | 2328-8957 2328-8957 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11167674 |
| source | DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Beta lactamases Care and treatment Drug resistance in microorganisms Editor's Choice Health aspects Microbiology Pivmecillinam Review Urinary tract infections |
| title | Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T00%3A48%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20the%20In%20Vitro%20Microbiological%20Activity%20of%20Mecillinam%20Against%20Common%20Uropathogens%20in%20Uncomplicated%20Urinary%20Tract%20Infection:%20Focus%20on%20Resistant%20Pathogens&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.au=Lodise,%20Thomas%20P&rft.date=2024-06&rft.volume=11&rft.issue=6&rft.spage=ofae296&rft.pages=ofae296-&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofae296&rft_dat=%3Cgale_pubme%3EA804159849%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067912629&rft_id=info:pmid/38868308&rft_galeid=A804159849&rfr_iscdi=true |